AutoImmune-AIMM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AutoImmune-AIMM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael H. Dragon who wrote (28)	3/12/1997 10:41:00 AM
From: organ	of 298

Mike, The info comes from an established neuroscientist studying MS, working towards a cure. In a conversation with him he mentioned that he was abandoning the oral tolerance route because scientists at AIMM have told him that the efficacy results to that point (Feb. 15 or so) were not statistically significant. I don't feel like he was trying to manipulate the market or anything like that because this was a professional scientific conversation. You are right that the phase 3 trials have not been unmasked yet, but the information I have certainly is not "official". I find it quite interesting how precipitous the drop in AIMM's stock has been in the past few weeks. My theory is that insiders who know the ongoing results of the trials (as I am now lucky enough to know too) are quietly dumping their shares. It seems that most of the time the value of shares of a biotech company increases as the clinical trials data are to be released, not decreases. About the placebo comment, my point is that the difference between placebo effect and the myloral effect was found not to be statistically significant, according to the claims of my researcher contact. Do what you will with this information. Best of luck! - Mark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next